Clinical Trials List
2007-09-17 - 2012-05-31
Phase II
Terminated8
ICD-10C53.9
Malignant neoplasm of cervix uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9180.9
Malignant neoplasm of cervix uteri, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 周宏學 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wen-Fang Cheng Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 陳寶珠 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 張正昌 Division of Obstetrics & Gynecology
- Hung-Cheng Lai Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
100 participants
-
Global
3720 participants
